SF3B1 and glioblastoma: Interestingly, pladienolide B treatment significantly decreased SF3B1 mRNA/protein levels in GBM cells (U-87/U-118 MG cells and primary-GBM cell cultures) and in the preclinical-xenograft GBM model (Fig. S5c-d).